Uric acid promotes neuronal differentiation of human placenta-derived mesenchymal stem cells in a time- and concentration-dependent manner*

Nailong Yang1, Lili Xu1, Peng Lin2, Jing Cui3

1 Department of Endocrinology, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, Shandong Province, China
2 Department of Endocrinology, Qilu Hospital of Shandong University, Jinan 250002, Shandong Province, China
3 VIP Department, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, Shandong Province, China

Abstract
Uric acid is an important, naturally occurring serum antioxidant. The present study investigates the use of uric acid for promoting proliferation and neuronal differentiation of mesenchymal stem cells derived from human placenta tissue. Human placenta-derived mesenchymal stem cells were pre-induced in the presence of either 0, 0.2, 0.4 or 0.8 mM uric acid in combination with 1 mM β-mercaptoethanol for 24 hours, followed by exposure to identical uric acid concentrations and 5 mM β-mercaptoethanol for 6 and 10 hours. Cells developed a neuronal-like morphology, with formation of interconnected process extensions, typical of neural cells. Immunocytochemistry and immunofluorescence staining showed neuron specific enolase positive cells were present in each group except the control group. A greater number of neuron specific enolase positive cells were observed in 0.8 mM uric acid in combination with 5 mM β-mercaptoethanol at 10 hours. After 24 hours of induction, Nissl bodies were detected in the cytoplasm of all differentiated cell groups except the control group and Nissl body numbers were greatest in human placenta-derived mesenchymal stem cells grown in the presence of 0.8 mM uric acid and 5 mM β-mercaptoethanol. These results suggest uric acid accelerates differentiation of human placenta-derived mesenchymal stem cells into neuronal-like cells in a time- and concentration-dependent manner.

Key Words: uric acid; human placenta-derived mesenchymal stem cells; differentiation; neural cells

Abbreviations: hPMSCs, human placenta-derived mesenchymal stem cells; BME, β-mercaptoethanol; NSE, neuron specific enolase

INTRODUCTION
Human placenta-derived mesenchymal stem cells (hPMSCs) have the potential to differentiate in vitro and in vivo, into neural cells, therefore providing a novel, therapeutic stem cell source for the treatment of neurodegenerative diseases, including Parkinson’s disease, brain ischemia and amyotrophic lateral sclerosis.[1-3]. Uric acid is the end product of purine nucleotide metabolism. Experimental, clinical and epidemiologic evidence suggest that hyperuricemia plays a role in the pathogenesis of certain disease processes, including hypertension, insulin resistance, type II diabetes, cardiovascular and cerebrovascular events.[4-8]. Recent studies have shown uric acid to be an important serum antioxidant involved in the scavenging of single oxygen, peroxyl and hydroxyl radicals, thus protecting cells from oxidative damage[9-10] and delaying the onset of Alzheimer’s disease and dementia.[11-12]. Uric acid also stimulates proliferation of some cell types including T cells[13] and endothelial progenitor cells[14] and has been shown to protect dopaminergic neurons.[15]. That is, uric acid has dual effects within the human body. Neuronal differentiation of mesenchymal stem cells (MSCs) is typically promoted using antioxidants including β-mercaptoethanol (BME), dimethyl sulfoxide and butylated hydroxyanisole[16]. In the present study, uric acid and BME were used to induce differentiation of hPMSCs into nerve cells in order to investigate the effects of uric acid during the differentiation process.

RESULTS
Morphology of isolated and cultured hPMSCs
Five days after initial hPMSCs seeding, phase-contrast microscopy revealed small, adherent cell colonies with fibroblast-like morphology (Figure 1A). Fibroblast-like cells continued to proliferate forming a homogeneous layer. hPMSCs reached 80–90% confluence 2 weeks later. Cell
passaging significantly accelerated cell growth and expansion, resulting in a more homogeneous culture with predominantly spindle-shaped morphology (Figure 1B).

Phenotyping of cultured hPMSCs
Immunofluorescence analysis revealed that hPMSCs were positive for CD44, a marker for mesenchymal stem cells (Figure 2A) and negative for CD34, a marker for hematopoietic cells (Figure 2B), indicating that the isolated cells were hPMSCs.

Effect of uric acid on hPMSCs proliferation
A methyl thiazolyl tetrazolium (MTT) assay indicated hPMSC proliferation was enhanced by uric acid in a dose-dependent manner (0.2, 0.4 and 0.8 mM). However, hPMSCs treated with 1.2 mM uric acid resulted in decreased proliferation. These results indicate that low and high concentrations of uric acid can accelerate and inhibit proliferation of hPMSCs respectively. The logarithmic growth phase of hPMSCs began at day 3 (Figure 3).

Uric acid induced Nissl bodies in hPMSCs
After neural cell induction of hPMSCs for 24 hours with 0, 0.2, 0.4 or 0.8 mM uric acid in combination with 5 mM BME, Giemsa staining was used to detect Nissl bodies in the cytoplasm of differentiated cells. Nissl bodies were detected in all groups except the control group (Figure 6). The quantity of Nissl bodies was most abundant in the 0.8 mM uric acid group.

DISCUSSION
MSCs can be induced to differentiate into various kinds of cells in vitro, including osteoblasts, adipocytes and nerve cells[17-20]. In addition, MSCs can be used to treat nervous system diseases and myocardial injury[21-23], promote the function of vascular cells and accelerate wound healing by promoting the formation of new blood vessel[23-25]. MSCs transplanted into animal models
display a protective effect towards damaged brain and spinal cord tissues\cite{26-27}.

Figure 5 Neuron specific enolase expression in human placenta-derived mesenchymal stem cells induced with different concentrations of uric acid (immunofluorescence staining).

Immunofluorescence microscopy (×100) images showing 0.8 mM (A), 0.4 mM (B), 0.2 mM (C), 0 mM (D) uric acid groups.

Increased concentrations of uric acid resulted in increased fluorescein isothiocyanate staining (green), especially within the 0.8 mM uric acid group.

Table 1 NSE positive cells (%)

| Group     | 6-hour induction | 10-hour induction |
|-----------|------------------|-------------------|
| 0.8 mM UA | 62.9⁺            | 81.8⁶             |
| 0.4 mM UA | 40.2⁺            | 53.6⁶             |
| 0.2 mM UA | 25.0⁺            | 45.9⁹             |
| 0 mM UA  | 17.2             | 32.9              |

Ten fields of view were randomly selected and 100 cells were quantified using light microscopy (×100).
The ratio of NSE positive cells in each group was calculated. ⁺P < 0.05 vs. 0 mM UA group; ⁹P < 0.05 vs. 6-hour induction (analysis of variance followed by post hoc analysis). NSE: Neuron specific enolase; UA: uric acid.

Figure 6 Nissl body formation within human placenta-derived mesenchymal stem cells following induction with 0.8 mM uric acid and 5 mM β-mercaptoethanol for 24 hours (Giemsa staining, light microscopy, ×200).

Nissl bodies stained dark blue in cytoplasm (arrows).

Data from this study indicate MSCs from placental tissue could act in an identical manner for similar therapeutic applications.

MSCs have been harvested from a number of tissues, including adipose, cord blood, bone marrow and embryonic\cite{28-30}. Recent evidence shows that cells derived from human placenta tissue have unlimited self-renewal capabilities, coupled with an ability to differentiate into many cell types, arousing increased attention for their use in regenerative medicine\cite{31}.

However, human placenta tissue is reported to contain limited numbers of mononuclear cells. Although hPMSCs can be successfully induced into nerve cells, the quantity of induced cells is not sufficient, therefore limiting their clinical application. Consequently, there is a requirement for obtaining sufficient hPMSC numbers and ensuring their efficient induction into neural cells.

There is at present, no uniform standard for the identification of hPMSCs. hPMSCs are typically identified using cell morphology characteristics, cell surface marker expression and their ability to differentiate through various lineages\cite{32-33}. In the present study, phase-contrast microscopy revealed hPMSCs with fibroblast-like morphology. Immunofluorescence analysis results showed that the cells were CD44 positive and CD34 negative, indicating a relatively pure hPMSC population was obtained.

Both uric acid and BME are powerful antioxidants that exist naturally in the human body\cite{34}. Using BME and dimethyl sulfoxide, Woodbury et al.\cite{35} reported that MSCs could be induced to differentiate into nerve cells. In the present study, we first investigated the influence of uric acid on promoting proliferation of hPMSCs. MTT assay data showed that uric acid used at low concentration (0.2, 0.4 and 0.8 mM) accelerates hPMSC proliferation, while at high concentration (1.2 mM), it inhibits hPMSC proliferation.

Interestingly, uric acid was found to accelerate differentiation of hPMSCs into neural cells in a time- and concentration-dependent manner, predominantly in cells treated with 0.8 mM uric acid.

In conclusion, uric acid accelerates proliferation of hPMSCs and their subsequent differentiation into neuronal-like cells in a time- and concentration-dependent manner. Using this method, we obtain greater numbers of hPMSCs and subsequent neuronal-like cells derived from hPMSCs. This may provide a new method for the scientific and clinical application of hPMSCs.

**MATERIALS AND METHODS**

**Design**

An *in vitro* comparative observation of repetitive measurements.

**Time and setting**

Experiments were performed in the Gout Laboratory of the Affiliated Hospital of Qingdao University Medical College, China, from March to August 2011.

**Materials**

Human placentas were provided by the Department of Obstetrics and Gynecology of Qingdao Marie Hospital, China. The parturient had no severe or communicable
diseases. Informed consent was obtained from the parturient (including abortion and voluntarily donation).

**Methods**

**Isolation and culture of hPMSCs**

Harvested placentas were washed several times in phosphate buffered saline (PBS) to remove blood cells and subsequently sheared into 1 mm × 1 mm × 1 mm pieces using eye scissors. Tissue digestion was performed using 0.1% collagenase II (Sigma, St. Louis, MO, USA) solution at 37°C for 45 minutes and cell filtration was performed using a 200 mesh sieve. The resulting cell sediment was obtained by centrifugation at 1000 r/min for 5 minutes at room temperature. The mononuclear cell fraction was separated by density gradient centrifugation and incubated in Dulbecco's modified Eagle's medium (DMEM)/F12 (Gibco, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS, HyClone, Logan, Utah, USA) at 37°C in a humidified atmosphere containing 5% CO₂ in a culture flask (T-175). Medium was replaced every 7 days thereafter. Non-adherent cells were progressively discarded by medium replacement. Cells were passaged to other culture flask (T-175) by trypsinization when MSCs reached 80% confluence. After passage, medium was replaced every 3 days. Cell morphology was observed using a phase-contrast inverted microscope (Olympus, Tokyo, Japan).

**Immunofluorescence analysis of hPMSCs surface markers**

hPMSCs (P3) were seeded into wells of a 6-well plate at a density of 5.0 × 10⁴ cells/well. On reaching 50–60% confluence, expanded hPMSCs were washed three times with PBS, fixed with 4% paraformaldehyde (pH 7.4, 30 minutes) and rinsed with PBS (3 × 5 minutes). Cells were incubated for 1 hour with appropriate fluorochrome-conjugated antibody, either CD44-FITC or CD34-FITC (eBioscience, San Diego, CA, USA), and immediately analyzed by immunofluorescence (Olympus).

**MTT detection for hPMSCs viability**

hPMSCs (P4) were digested using 0.25% trypsin and seeded into four 96-well plates at a density of 5.0 × 10⁴ cells per cm². Experimentation was performed across five groups: untreated control, 0.8, 0.4, 0.2 and 0 mM uric acid groups.

On reaching 50–60% confluence, hPMSCs were pre-induced in serum-free culture medium containing 1 mM BME (Sigma) and uric acid (0, 0.2, 0.4 and 0.8 mM) for 24 hours. This was replaced with 10% HI-FBS containing culture medium with 5 mM BME and identical respective concentrations of uric acid for 6 or 10 hours. Neural-like cells were identified using immunocytochemical and immunofluorescent staining. Giemsa staining was performed 24 hours after induction. Untreated group hPMSCs were cultured in DMEM/F12 medium supplemented with 10% HI-FBS in absence of BME or uric acid.

**Immunocytochemical staining for NSE expression**

hPMSCs were washed with PBS (3 × 10 minutes) and fixed with 4% paraformaldehyde (30 minutes/room temperature). After further PBS washes (3 × 10 minutes), cells were permeabilized with 0.1% Triton X-100 for 10 minutes prior to exposure to 3% bovine serum albumin (Sigma) for 15 minutes and incubation for 1 hour with primary rabbit anti-human NSE monoclonal antibody (1:100 dilution; Saierbio Corporation, Tianjin, China). Cells were washed three times in PBS and incubated for 30 minutes with secondary goat anti-rabbit antibody (1:200 dilution; BIOS Corporation, Sapulpa, OK, USA). Cells were then treated with avidin-biotin (BIOS Corporation) for 30 minutes, washed with PBS (2 × 5 minutes), 3',3'-diaminobenzidine tetrahydrochloride dehydrate (BIOS Corporation) staining substrate was mixed with the cells and left to react for 5 minutes. Addition of PBS for 5 minutes stopped the reaction and cells were washed twice with PBS. Finally, cells from each group were visualized by microscopy (Olympus) and photographed with a Nikon camera (magnification, × 200; Tokyo, Japan).

**Immunofluorescence staining for NSE expression**

hPMSCs were washed, fixed and permeabilized using the same methods as immunocytochemistry. The cells were incubated for 1 hour with the primary rabbit anti-human NSE monoclonal antibody (dilution at 1:100). After the reaction with the primary antibody, the cells were washed three times in PBS and incubated for 30 minutes with the secondary fluorescein isothiocyanate labeled goat anti-rabbit NSE antibody (dilution at 1:200; eBioscience). The cells were washed twice for 5 minutes with PBS, visualized using immunofluorescence microscopy (Olympus) and photographed with a Nikon camera (magnification, × 100).

**Giemsa staining for Nissl body formation**

hPMSCs were washed with PBS (3 × 10 minutes) and fixed with 4% paraformaldehyde (30 minutes/room temperature) prior to subsequent washing with PBS (3 × 10 minutes) and treatment with 1 mL/well Giemsa stain (Sigma). Cells were incubated in a box with 5% CO₂ at 37°C for 30 minutes, washed with PBS and visualized using light microscopy (Olympus). Photographs were
taken using a Nikon camera (magnification, × 400).

**Statistical analysis**

Data was expressed as a mean. Results were analyzed using analysis of variance followed by post hoc assessment using SPSS 17.0 software (SPSS, Chicago, IL, USA). A value of P < 0.05 was considered statistically significant.

**Acknowledgments:** We thank the Department of Obstetrics and Gynecology of Qingdao Marie Hospital in China for the placenta tissues and the Gout Laboratory of the Affiliated Hospital of Qingdiao University Medical College for their cell culture technical assistance and use of experimental equipment.

**Author contributions:** Nailong Yang was responsible for the experimental concept, design, guidance and ethical approval. Jing Cui was responsible for conducting the experimental procedures, providing the images and writing the manuscript. Lili Xu and Peng Lin were responsible for image processing, data analysis and technical and informational support.

**Ethical approval:** The study was approved by the Qingdao Municipal Hospital Medical Ethics Committee and followed guidelines from the “Helsinki Declaration Requirements”.

**REFERENCES**

[1] Silani V, Cova L, Corbo M, et al. Stem-cell therapy for amyotrophic lateral sclerosis. Lancet. 2004;364(9429):200-202.

[2] Cui YF, Hargus G, Xu JC, et al. Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery in Parkinsonian mice. Brain. 2010;133(Pt 1):189-204.

[3] Yu SJ, Soncini M, Kaneko Y, et al. Amnion: a potent graft source for cell therapy in stroke. Cell Transplant. 2009;18(2):111-118.

[4] Johnson RJ, Segal MS, Srivivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol. 2005;16(7):1909-1919.

[5] Ishizaka N, Ishizaka Y, Toda E, et al. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 2005;25(5):1038-1044.

[6] Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69(9):928-933.

[7] Bos MJ, Koudstaal PJ, Hofman A, et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37(6):1503-1507.

[8] Strasak AM, Kelleher CC, Brant LJ, et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol. 2008;125(2):232-239.

[9] Sautin YF, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):608-619.

[10] Amaro S, Soy D, Obach V, et al. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke. 2007;38(7):2173-2175.

[11] Euser SM, Hofman A, Westendorp RG, et al. Serum uric acid and cognitive function and dementia. Brain. 2009;132(Pt 2):377-382.

[12] Schretlen DJ, Inscorre AB, Jinnah HA, et al. Serum uric acid and cognitive function in community-dwelling older adults. Neuropsychology. 2007;21(1):136-140.

[13] Hu DE, Moore AM, Thomsen LL, et al. Uric acid promotes tumor immune rejection. Cancer Res. 2004;64(15):5059-5062.

[14] Zhao X, Ji QH, Tang CW, et al. Effect of uric acid in different concentrations on the proliferation of human umbilical vein endothelial cells in vitro. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2007;11(6):1189-1191.

[15] Guerreiro S, Ponceau A, Toulouse D, et al. Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J Neurochem. 2008;109(4):1118-1128.

[16] Li P, Blesch A, Tuszyński MH. Induction of bone marrow stromal cells to neurons: differentiation, transdifferentiation, or artifact? J Neurosci Res. 2004;77(2):174-191.

[17] Miao Z, Jin J, Chen L, et al. Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. Cell Biol Int. 2006;30(9):681-687.

[18] Hwang JH, Shim SS, Seok OS, et al. Comparison of cytokine expression in mesenchymal stem cells from human placenta, cord blood, and bone marrow. J Korean Med Sci. 2009;24(4):547-554.

[19] Portmann-Lanz CB, Schoerberlin A, Huber A, et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol. 2006;194(3):664-673.

[20] Yen BL, Huang HI, Chien CC, et al. Isolation of multipotent cells from human term placenta. Stem Cells. 2005;23(1):3-9.

[21] WuZY, Hui GZ, Lu Y, et al. Transplantation of human amniotic epithelial cells improves hindlimb function in rats with spinal cord injury. Chin Med J (Engl). 2006;119(24):2101-2107.

[22] Ichim TE, Solano F, Brenes R, et al. Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathy. Reprod Biomed Online. 2008;16(6):898-905.

[23] Tang J, Xie Q, Pan G, et al. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg. 2006;30(2):353-361.

[24] Wu Y, Chen L, Scott PG, et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007;25(10):2648-2659.

[25] Prather WR, Toren A, Meiron M, et al. The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. Cytotherapy. 2009;11(4):427-434.

[26] Sankar V, Muthusamy R. Role of human amniotic epithelial cell transplantation in spinal cord injury repair research. Neuroscience. 2003;118(1):11-17.

[27] Mautes AE, Liu J, Brandweide J, et al. Regional energy metabolism following short-term neural stem cell transplantation into the injured spinal cord. J Mol Neurosci. 2004;24(2):227-236.

[28] Tondreau T, Lagneaux L, Dejeneffe M, et al. Differentiative potential of human metanephric mesenchymal cells. Exp Hematol. 2002;30(12):1454-1462.

[29] Gaspard N, Vanderhaeghen P. Mechanisms of neural specification from embryonic stem cells. Curr Opin Neurobiol. 2010;20(2):37-43.

[30] Alfred R, Taiani JT, Krawetz RJ, et al. Large-scale production of murine embryonic stem cell-derived osteoblasts and chondrocytes on microcarriers in serum-free media. Biomaterials. 2011;32(26):6006-6016.

[31] Parolini O, Alvano F, Bagnara GP, et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells. 2008;26(2):300-311.

[32] Romanov YA, Darevskaya AN, Merzlikina NV, et al. Mesenchymal stem cells from human bone marrow and adipose tissue: isolation, characterization, and differentiation potentialities. Bull Exp Biol Med. 2005;140(1):138-143.

[33] Lei Z, Yongda L, Jun M, et al. Culture and neural differentiation of rat bone marrow mesenchymal stem cells in vitro. Cell Biol Int. 2007;31(9):916-923.

[34] Woodbury D, Schwarz EJ, Prockop DJ, et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res. 2000;61(4):364-370.

(Edited by Yang XF, Bao JF/Su LL/Song LP)